Correlation of immunomodulatory and therapeutic activities of interferon and interferon inducers in metastatic disease

Paul L. Black, Hamblin Phillips, Henry R. Tribble, Robin Pennington, Mark Schneider, James E Talmadge

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The mechanism of therapeutic activity of recombinant murine interferon‐gamma (rMu IFN‐γ) and the IFN inducer polyinosinic‐polycytidylic acid solubilized with poly‐L‐lysine in carboxy methyl cellulose (pICLC) in treating metastatic disease was investigated by comparing effector cell augmentation with therapeutic activity in mice bearing experimental lung metastases (B16‐BL6 melanoma). Effector cell functions in spleen, peripheral blood, and lung (the organ with tumor) were tested after 1 and 3 weeks of rMu IFN‐γ or pICLC administration (intravenous, three times a week). In these studies, natural killer (NK), lymphokine‐activated killer (LAK), cytolytic T lymphocytes (CTL) (against specific and nonspecific targets), and macrophage tumoricidal and tumoristatic activities were measured. rM IFN‐γ and pICLC had therapeutic activity and immunomodulatory activity in most assays of immune function examined. Specific CTL activity of pulmonary parenchymal mononuclear cells (PPMC), but not in splenocytes or peripheral blood lymphocytes (PBL), during week 3 and not during week 1, correlated with the therapeutic activity of rMu IFN‐γ and of pICLC. Macrophage tumoricidal activity in PPMC, but not in alveolar macrophages, also correlated with the therapeutic activity of rMu IFN‐γ, but the opposite was true for the therapeutic activity of pICLC. NK activity of PPMC, but not of splenocytes or PBL, during week 1 correlated with the therapeutic activity of pICLC; in contrast, NK activity at any site did not correlate with the therapeutic activity of rMu IFN‐γ. LAK activity at any site did not correlate with the therapeutic activity of either agent.

Original languageEnglish (US)
Pages (from-to)377-392
Number of pages16
JournalJournal of Cellular Biochemistry
Volume36
Issue number4
DOIs
StatePublished - Jan 1 1988

Fingerprint

Interferon Inducers
Methylcellulose
Interferons
Blood
T-cells
Lymphocytes
Macrophages
Lung
Bearings (structural)
Therapeutics
Cells
T-Lymphocytes
Tumors
Assays
Alveolar Macrophages
Intravenous Administration
Acids
Melanoma
Spleen
Neoplasm Metastasis

Keywords

  • anti‐tumor activity
  • cytolytic T lymphocyte (CTL)
  • double‐stranded polyribonucleotides
  • interferon‐gamma
  • mechanism of therapeutic activity
  • poly (I,C)‐LC
  • preclinical models
  • treatment of metastases
  • tumor‐specific

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Correlation of immunomodulatory and therapeutic activities of interferon and interferon inducers in metastatic disease. / Black, Paul L.; Phillips, Hamblin; Tribble, Henry R.; Pennington, Robin; Schneider, Mark; Talmadge, James E.

In: Journal of Cellular Biochemistry, Vol. 36, No. 4, 01.01.1988, p. 377-392.

Research output: Contribution to journalArticle

Black, Paul L. ; Phillips, Hamblin ; Tribble, Henry R. ; Pennington, Robin ; Schneider, Mark ; Talmadge, James E. / Correlation of immunomodulatory and therapeutic activities of interferon and interferon inducers in metastatic disease. In: Journal of Cellular Biochemistry. 1988 ; Vol. 36, No. 4. pp. 377-392.
@article{a7104bf166d9456f8a9a7f53285904ec,
title = "Correlation of immunomodulatory and therapeutic activities of interferon and interferon inducers in metastatic disease",
abstract = "The mechanism of therapeutic activity of recombinant murine interferon‐gamma (rMu IFN‐γ) and the IFN inducer polyinosinic‐polycytidylic acid solubilized with poly‐L‐lysine in carboxy methyl cellulose (pICLC) in treating metastatic disease was investigated by comparing effector cell augmentation with therapeutic activity in mice bearing experimental lung metastases (B16‐BL6 melanoma). Effector cell functions in spleen, peripheral blood, and lung (the organ with tumor) were tested after 1 and 3 weeks of rMu IFN‐γ or pICLC administration (intravenous, three times a week). In these studies, natural killer (NK), lymphokine‐activated killer (LAK), cytolytic T lymphocytes (CTL) (against specific and nonspecific targets), and macrophage tumoricidal and tumoristatic activities were measured. rM IFN‐γ and pICLC had therapeutic activity and immunomodulatory activity in most assays of immune function examined. Specific CTL activity of pulmonary parenchymal mononuclear cells (PPMC), but not in splenocytes or peripheral blood lymphocytes (PBL), during week 3 and not during week 1, correlated with the therapeutic activity of rMu IFN‐γ and of pICLC. Macrophage tumoricidal activity in PPMC, but not in alveolar macrophages, also correlated with the therapeutic activity of rMu IFN‐γ, but the opposite was true for the therapeutic activity of pICLC. NK activity of PPMC, but not of splenocytes or PBL, during week 1 correlated with the therapeutic activity of pICLC; in contrast, NK activity at any site did not correlate with the therapeutic activity of rMu IFN‐γ. LAK activity at any site did not correlate with the therapeutic activity of either agent.",
keywords = "anti‐tumor activity, cytolytic T lymphocyte (CTL), double‐stranded polyribonucleotides, interferon‐gamma, mechanism of therapeutic activity, poly (I,C)‐LC, preclinical models, treatment of metastases, tumor‐specific",
author = "Black, {Paul L.} and Hamblin Phillips and Tribble, {Henry R.} and Robin Pennington and Mark Schneider and Talmadge, {James E}",
year = "1988",
month = "1",
day = "1",
doi = "10.1002/jcb.240360407",
language = "English (US)",
volume = "36",
pages = "377--392",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Correlation of immunomodulatory and therapeutic activities of interferon and interferon inducers in metastatic disease

AU - Black, Paul L.

AU - Phillips, Hamblin

AU - Tribble, Henry R.

AU - Pennington, Robin

AU - Schneider, Mark

AU - Talmadge, James E

PY - 1988/1/1

Y1 - 1988/1/1

N2 - The mechanism of therapeutic activity of recombinant murine interferon‐gamma (rMu IFN‐γ) and the IFN inducer polyinosinic‐polycytidylic acid solubilized with poly‐L‐lysine in carboxy methyl cellulose (pICLC) in treating metastatic disease was investigated by comparing effector cell augmentation with therapeutic activity in mice bearing experimental lung metastases (B16‐BL6 melanoma). Effector cell functions in spleen, peripheral blood, and lung (the organ with tumor) were tested after 1 and 3 weeks of rMu IFN‐γ or pICLC administration (intravenous, three times a week). In these studies, natural killer (NK), lymphokine‐activated killer (LAK), cytolytic T lymphocytes (CTL) (against specific and nonspecific targets), and macrophage tumoricidal and tumoristatic activities were measured. rM IFN‐γ and pICLC had therapeutic activity and immunomodulatory activity in most assays of immune function examined. Specific CTL activity of pulmonary parenchymal mononuclear cells (PPMC), but not in splenocytes or peripheral blood lymphocytes (PBL), during week 3 and not during week 1, correlated with the therapeutic activity of rMu IFN‐γ and of pICLC. Macrophage tumoricidal activity in PPMC, but not in alveolar macrophages, also correlated with the therapeutic activity of rMu IFN‐γ, but the opposite was true for the therapeutic activity of pICLC. NK activity of PPMC, but not of splenocytes or PBL, during week 1 correlated with the therapeutic activity of pICLC; in contrast, NK activity at any site did not correlate with the therapeutic activity of rMu IFN‐γ. LAK activity at any site did not correlate with the therapeutic activity of either agent.

AB - The mechanism of therapeutic activity of recombinant murine interferon‐gamma (rMu IFN‐γ) and the IFN inducer polyinosinic‐polycytidylic acid solubilized with poly‐L‐lysine in carboxy methyl cellulose (pICLC) in treating metastatic disease was investigated by comparing effector cell augmentation with therapeutic activity in mice bearing experimental lung metastases (B16‐BL6 melanoma). Effector cell functions in spleen, peripheral blood, and lung (the organ with tumor) were tested after 1 and 3 weeks of rMu IFN‐γ or pICLC administration (intravenous, three times a week). In these studies, natural killer (NK), lymphokine‐activated killer (LAK), cytolytic T lymphocytes (CTL) (against specific and nonspecific targets), and macrophage tumoricidal and tumoristatic activities were measured. rM IFN‐γ and pICLC had therapeutic activity and immunomodulatory activity in most assays of immune function examined. Specific CTL activity of pulmonary parenchymal mononuclear cells (PPMC), but not in splenocytes or peripheral blood lymphocytes (PBL), during week 3 and not during week 1, correlated with the therapeutic activity of rMu IFN‐γ and of pICLC. Macrophage tumoricidal activity in PPMC, but not in alveolar macrophages, also correlated with the therapeutic activity of rMu IFN‐γ, but the opposite was true for the therapeutic activity of pICLC. NK activity of PPMC, but not of splenocytes or PBL, during week 1 correlated with the therapeutic activity of pICLC; in contrast, NK activity at any site did not correlate with the therapeutic activity of rMu IFN‐γ. LAK activity at any site did not correlate with the therapeutic activity of either agent.

KW - anti‐tumor activity

KW - cytolytic T lymphocyte (CTL)

KW - double‐stranded polyribonucleotides

KW - interferon‐gamma

KW - mechanism of therapeutic activity

KW - poly (I,C)‐LC

KW - preclinical models

KW - treatment of metastases

KW - tumor‐specific

UR - http://www.scopus.com/inward/record.url?scp=0023891879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023891879&partnerID=8YFLogxK

U2 - 10.1002/jcb.240360407

DO - 10.1002/jcb.240360407

M3 - Article

VL - 36

SP - 377

EP - 392

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 4

ER -